Supernus Pharmaceuticals Inc. (SUPN) Shares Down 3.3%
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) dropped 3.3% during mid-day trading on Thursday . The company traded as low as $20.84 and last traded at $20.87, with a volume of 526,560 shares trading hands. The stock had previously closed at $21.58.
SUPN has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research note on Wednesday. Jefferies Group reaffirmed a “buy” rating and set a $23.00 target price (up from $19.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, May 12th. TheStreet raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, March 29th. Northland Securities reaffirmed an “outperform” rating and set a $22.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, March 11th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $24.00 target price on shares of Supernus Pharmaceuticals in a research note on Saturday, April 2nd. Five equities research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus target price of $23.00.
The company has a 50-day moving average of $19.28 and a 200-day moving average of $15.57. The stock has a market capitalization of $1.04 billion and a P/E ratio of 62.46.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.09 by $0.01. The business had revenue of $43 million for the quarter, compared to the consensus estimate of $45.33 million. During the same quarter in the prior year, the company earned $0.02 earnings per share. Supernus Pharmaceuticals’s revenue was up 53.0% compared to the same quarter last year. On average, equities analysts forecast that Supernus Pharmaceuticals Inc. will post $0.62 earnings per share for the current fiscal year.
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 30,762 shares of the firm’s stock in a transaction dated Monday, April 11th. The shares were sold at an average price of $16.49, for a total transaction of $507,265.38. Following the sale, the vice president now directly owns 57,306 shares of the company’s stock, valued at approximately $944,975.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Several large investors have recently added to or reduced their stakes in SUPN. Whitebox Advisors LLC purchased a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $1,014,000. Numeric Investors LLC boosted its stake in Supernus Pharmaceuticals by 101.8% in the fourth quarter. Numeric Investors LLC now owns 78,500 shares of the specialty pharmaceutical company’s stock valued at $1,055,000 after buying an additional 39,600 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its stake in Supernus Pharmaceuticals by 15.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 123,600 shares of the specialty pharmaceutical company’s stock valued at $1,662,000 after buying an additional 16,300 shares in the last quarter. Marshall Wace LLP purchased a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $2,345,000. Finally, New York State Common Retirement Fund boosted its stake in Supernus Pharmaceuticals by 3.7% in the fourth quarter. New York State Common Retirement Fund now owns 205,981 shares of the specialty pharmaceutical company’s stock valued at $2,768,000 after buying an additional 7,299 shares in the last quarter.
Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.